Close Menu

NEW YORK — OpGen last week filed an amended prospectus with US regulators to sell a mix of stock and warrants to raise up to $10.4 million to help fund its planned acquisition of German molecular diagnostics firm Curetis.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.